The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Matching-adjusted indirect treatment comparisons (MAIC) of sotorasib vs trifluridine/tipiracil (T/T) and regorafenib as monotherapy in chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC).
 
Timothy Jay Price
Honoraria - SERVIER
Consulting or Advisory Role - Amgen (Inst); Astrazeneca (Inst); BMS (Inst); Merck
Research Funding - AMGEN (Inst)
Travel, Accommodations, Expenses - Amgen
 
Scott Kopetz
Stock and Other Ownership Interests - Frontier Medicines; Iylon; Lutris; Navire; Xilis
Consulting or Advisory Role - Abbvie; Accademia Nazionale Di Medicina (ACCMED); Amal Therapeutics; Amgen; AstraZeneca/MedImmune; Bayer Health; Bicara Therapeutics; Black Diamond Therapeutics; Boehringer Ingelheim; Bristol-Myers Squibb/Medarex; Cardiff Oncology; Carina Biotech; CureTeq; EMD Serono; Endeavor BioMedicines; Flame Biosciences; Foundation Medicine; Frontier Medicines; Genentech; Genomic Health; Gilead Sciences; GlaxoSmithKline; HalioDx; Harbinger Oncology, Inc; Holy Stone Healthcare; Inivata; Ipsen; Iylon; Jacobio; Jazz Pharmaceuticals; Johnson & Johnson/Janssen; Lilly; Lutris; Merck; Mirati Therapeutics; NeoGenomics Laboratories; Novartis; Numab; Ono Pharmaceutical; Pfizer; Redx Pharma; Repare Therapeutics; Replimune; Servier; Taiho Pharmaceutical; Takeda; Tempus; Xilis; Zentalis
Research Funding - Amgen; Array BioPharma; Biocartis; Daiichi Sankyo; EMD Serono; Genentech/Roche; Guardant Health; Lilly; MedImmune; Novartis; Sanofi
 
Yasutoshi Kuboki
Honoraria - Bristol-Myers Squibb Japan; Lilly Japan; Taiho Pharmaceutical
Consulting or Advisory Role - Amgen; Boehringer Ingelheim; Takeda
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Janssen Oncology (Inst); Lilly (Inst); Merck Serono (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Amgen
 
Hans Prenen
Honoraria - Amgen; AstraZeneca; Bayer; Roche; Sanofi
Consulting or Advisory Role - Biocartis; cureteq
 
Istvan Matyas Majer
Employment - Amgen
Stock and Other Ownership Interests - Amgen
Travel, Accommodations, Expenses - Amgen
 
Marko Rehn
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Emily Chan
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Marwan Fakih
Honoraria - Amgen
Consulting or Advisory Role - Amgen; Bayer; BMS; Eisai; GlaxoSmithKline; Incyte; Merck; Mirati Therapeutics; Nouscom; Pfizer; Roche/Genentech; Seagen; Taiho Pharmaceutical
Speakers' Bureau - Guardant Health
Research Funding - Amgen (Inst); Verastem (Inst)